The clinical usefulness of the urinary excretion of three bone resorption markers is compared in patients after renal transplantation and in tumour patients with and without bone metastases. The markers were the 3-hydroxypyridinium derivatives pyridinoline and deoxypyridinoline (pyridinium cross-links; measured by a polyclonal enzyme immunoassay), the cross-linked N-telopeptid-to-helix domain of type I collagen and the destruction products of type I collagen metabolism crossreacting with a peptide sequence of the (XI-chain of the C-terminal telopeptide region of type I collagen (Crossl.apsl?").
correlation coefficients for the different markers were between + O' 35 and + 0·65 in patients receiving renal transplants, and between + O'58 and + 0·84 in patients with bone metastases.
In conclusion, in patients with metabolic and malignant bone diseases there are marked differences in the diagnostic performance of different biochemical markers of bone resorption. It is suggested that this may reflect the different facets of bone resorption or the different metabolic fates of the marker substances examined.
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A lot of putative biochemical markers of bone resorption can now be measured by commercially available immunoassays. ' In the present communication the clinical usefulness of three markers are compared: (a) the 3-hydroxypyridinium derivatives pyridineline and deoxypyridinoline which cross-link adjacent molecules of bone collagen; (b) the cross-linked N-telopeptid-to-helix domain of type I collagerr'; and (c) destruction products Correspondence: Dr med Wolfgang Withold. of type I collagen metabolism cross-reacting with a peptide sequence of the (Xl-chain of the Cterminal telopeptide region of type I collagen (CrossLapsTM). 3 At present no information is available concerning the diagnostic utility of these analytes for bone disease in patients after renal transplantation in whom increased bone resorption can be observed which may be due to the combined action of the immunosuppressive agents used (i.e., cyclosporin A and methylprednisolonej.t-' In tumour patients osteolytic processes may increase the rate of release of components derived from bone resorption into the circulation.P
MATERIALS AND METHODS

Patients with renal transplants
We examined 32 urine samples (the second urine passed between 0800 hand 1000 h) as well as the corresponding venous blood specimens (serum as well as plasma anticoagulated with dipotassium ethylenediaminetetracetate) from 16 patients (6 men, 10 women) who underwent cadaveric renal transplantation. The age-range was 30-66 years. All patients received cyclosporin A, azathioprine and methylpredinisolone. Urine and blood specimens were drawn on two occasions from each patient. The median (range) sampling times after transplantation were 9(5-36) and 34(20-162) days, respectively.
Patients with malignancies
We examined the second morning urine sample from 52 tumour patients (17 men, 35 women; age-range: 26-74 years) with different malignant diseases. According to the results of 99mTc_ methylene diphosphonate bone scintigraphy the patients were classed into the following groups: no pathological findings (group A; n = 25); pathological findings which cannot be attributed to benign disease (group B; n = 27).
Determination of the urinary excretion of pyridinium cross-links of collagen
The urinary concentration of pyridinium crosslinks of collagen was determined by a competitive enzyme immunoassay (Collagen Cross-links™; Metra Biosystems Inc, Palo Alto, CA, USA) employing a polyclonal antibody against pyridinoline. This antibody shows 100% crossreactivity with deoxypyridinoline and reacts preferentially with the free fractions of these two cross-links. A calibration curve was constructed using a four-parameter curve fitting equation. Urinary excretion is given as nmol pyridinoline equivalents/mol creatinine.
The following reference interval (5th-95th percentile) for excretion of pyridinium crosslinks was established in apparently healthy people using urine samples obtained between 0800 hand 1000 h: 9-70 nmol pyridinoline equivalents/rnmol creatinine (n = 40; 20 men and 20 women; age range: 28-58 years). The reference range was independent of sex (P> 0,1).
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Determination of the urinary excretion of N-telopeptides of type I collagen
The urinary excretion of N-telopeptides of type I collagen was measured with an enzyme immunoassay (Osteomark'"; Ostex International, Seattle, WA, USA) using a monoclonal antibody directed against the N-telopeptid-to-helix intermolecular cross-linking domain of type I collagen isolated from human adolesecent urine. The antibody is claimed to react with a conformational epitope which is specific for the cross-linking domain of bone collagen. The calibration of the assay is based upon human type I collagen digested with bacterial collagenase in a reproducible manner. The urinary excretion values are expressed as jlmol bone collagen equivalents/mol creatinine.
The following reference interval (5th-95th percentile) for excretion of N-telopeptides was established in apparently healthy people using urine samples obtained between 0800 hand 1000 h: 9--65jlmol bone collagen equivalents/ mol creatinine (n = 40; 20 men and 20 women; age range: 28-58 years). The reference range was independent of sex (P>O·I).
Determination of the urinary excretion of CrossLaps™
The urinary excretion of CrossLaps ™ was determined with an enzyme immunoassay (Crossl.aps'P" ELISA, Osteometer A/S, Rodovre, Denmark). This assay is based upon an immobilized synthetic peptide derived from a sequence in the lXI-chain of the C-telopeptide region of type I collagen. During incubation with an antibody raised to this peptide, a competition takes place between the immobilized peptide and the breakdown products of the lXI-chain of type I collagen in urine. The excretion values are given as jlmol Crossl.apsf" equivalents/mol creatinine (M, = 868).
The following reference interval (5th-95th percentile) for excretion of Crossl.apsl''" was established in apparently healthy people using urine samples obtained between 0800 hand 1000 h: 12-303 jlmol CrossLaps ™ equivalents/ mol creatinine (n = 40; 20 men and 20 women; age range: 28-58 years). The reference range was independent of sex (P> 0,1).
Determination of creatinine concentration in urine
Urine creatinine was measured using the Hitachi/BM 704 analyser (Boehringer Mannheim GmbH, Mannheim, Germany) employing a kinetic modification of the Jaffe procedure.' Determination of bone alkaline phosphatase mass concentration in serum Bone alkaline phosphatase mass concentration was determined by an immunoradiometric assay (Tandem'v-R OstaseI'"; Hybritech Inc, San Diego, CA, USA; No. 3040 BE) employing two monoclonal antibodies against two different epitopes of' the bone alkaline phosphatase molecule. A calibration curve was constructed by linear interpolation between the plotted analytical results.
Determination of 'intact' parathyroid hormone concentrations in plasma
Intact parathyroid hormone concentration was determined by using Nvtact'" PTH (INCSTAR Corporation, Stillwater, Minnesota, USA, No. 22800).
RESULTS
Discriminating power of biochemical markers of bone resorption in patients receiving renal transplants
After renal transplantation the urinary excretion of pyridinium cross-links showed a significant increase with time (P < O·l). In contrast there was no significant increase with time in the urinary excretion of the other two bone resorption markers ( Fig. I and Table I ).
Comparing the values obtained after renal transplantation with those of apparently healthy people by Z score analysis revealed that the urinary excretion of N-telopeptides showed a higher discriminating power (P<O'OOI) than that of pyridinium cross-links and Crossl.aps'P' ( Table 2 ).
Statistical analysis
The statistical methods employed include the U-test according to Wilcoxon, Mann and Whitney (two-tailed) for unpaired samples, Wilcoxon's ranked sum test for paired samples (two-tailed) and linear correlation coefficients." The discriminating power was estimated by calculating the Z scores (for explanations see Results). The accuracy was determined as the area under the receiver-operating characteristic curve.
Relationship between the examined biochemical markers of bone metabolism in patients receiving renal transplants
The relationship between the resorption markers was characterized by linear correlation coefficients between +0·35 and +0·65. There was a lack of correlation between the urinary excretion values of all bone resorption markers and parathyroid hormone concentrations at all times after renal transplantation (P>0·05). In contrast, all bone resorption markers correlated with bone Mean (SEM) is given. alkaline phosphatase mass concentrations (P<O'01) ( Table 3 ).
Discriminating power of biochemical markers of bone resorption in patients with bone metastases
In patients without pathological findings in bone scintigraphy the urinary excretion values of all bone resorption markers did not significantly differ from those of apparently healthy people (P> 0,05). In patients with pathological findings in bone scintigraphy the urinary excretion values of pyridinium cross-links and N-telopeptides were significantly higher than in those without pathological findings (P<O·OOI for pyridinium cross-links, P<O'OI for N-telopeptides). Patients with pathological findings in bone scinti- 
group A) and with pathological findings in bone scintigraphy (group B)
Correlation coefficients graphy showed a higher mean value in the urinary excretion of Crossl.apsf'" than patients without pathological findings; however, this difference did not reach significance level (P>O·I) ( Table 4 ).
Comparing patients with and without pathological findings in bone scintigraphy by Z score analysis revealed that the discriminating power of pyridinium cross-links and of N-telopeptides was superior to that of Cross LapsTM. The urinary excretion of pyridinium cross-links showed a slightly but not significantly (P=0'06) higher Z score value than N-telopeptides ( coefficients between + O'580 and + 0·844 (P < 0·0 1). In patients without pathological findings in bone scintigraphy there was no correlation between the urinary excretion of Crossl.apsl'f and the other bone resorption markers (P>O·05) ( Table 6 ).
Receiver-operating characteristic (ROC) plots for different biochemical markers of bone resorption in tumour patients
To evaluate the efficacy of the biochemical markers of bone resorption to discriminate between patients with and without pathological findings in bone scintigraphy, threshold values were fixed corresponding to the 10th, 20th, ... , 90th percentile of the distribution of the urinary excretion of these markers in all of 52 tumour patients examined. The accuracy was 0·81 for pyridinium cross-links, 0·76 for the N-telopeptides and 0·61 for Crossl.aps''?" (Fig. 2) .
DISCUSSION
There are several ways to examine the clinical usefulness of a putative biochemical marker of bone resorption." comparison of values with a 'gold standard' (e.g., bone histology and histomorphometry); demonstration that the marker values rise under conditions known to increase bone resorption and fall under conditions known to decrease bone resorption; or show a significant correlation with established markers of bone resorption. This communication compares three different markers of bone resorption with respect to their clinical usefulness in the diagnosis of metastatic spread into bone and in the follow-up of nephrological patients receiving renal transplants.
resorption more specifically than pyridinium cross-links.?
In contrast, the Crossl.aps'P' assay employs an antibody showing specificity for a peptide sequence of the C-terminal telopeptide of type I collagen which is common to all type I collagen molecules.' This may compromise the bone specificity of this analyte. However, in the absence of an increased collagen turnover of other tissues, CrossLaps™ might be suitable as a bone resorption marker for the following reasons: the urinary excretion values of Cross-Laps™ correlate with those of hydroxyproline (which is an established marker of bone resorptionj.!' the values are increased in more than one-third of early-postmenopausal women;' oestrogen replacement therapy yields a highly significant mean decrease (61%) in the values; 14 and analysis of the discriminating power reveals mean Z score values of I· 5 and 4-4 (as compared with sex-and age-adjusted controls) in patients with primary hyperparathyroidism and Paget's disease, respectively."
In the present communication the clinical usefulness of the Crossl.aps'l'" assay was found to be inferior to that of N-telopeptides and pyridinium cross-links both in tumour patients and in those receiving renal transplants. Similarly Garnero et al. 15 showed that in patients with hyperthyroidism the increase of the Cross-LapsTM values was far less pronounced than that of pyridinium cross-links. It must be taken into account that nothing is known about the metabolic fate of the bone resorption markers under investigation and to which extent different diseases might affect the metabolic and renal clearance of these analytes.
Increased urinary excretion values of pyridinium cross-links in patients with metastatic prostatic carcinoma have already been described." Differentiating patients with and without bone metastases yielded an 'accuracy' value of 0·81 essentially corresponding to the value which has previously been found by another group (0,72 for the urinary excretion of hydroxylysylpyridinoline as determined by HPLC analysis)."
Interestingly, some biochemical markers of bone metabolism (e.g., the carboxy-terminal propeptide of procollagen type I) do not show a significant increase in postmenopausal osteoporotic women (in whom one might expect increased bone turnover) but a rapid and marked decrease after treatment (e.g., with diphosphonates).' In patients receiving renal 
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Type I collagen accounts for more than 90% of the organic matrix of bone and consists of two CX1-and one cx2-chain. The N-telopeptide domain of bone collagen is uniquely enriched in cxl(I)--a2(I) cross-links compared with type I collagen of other tissues; and an antibody directed to a conformation epitope of type I collagen induced by these cross-links might therefore recognize a strictly bone-specific feature of collagen.? The urinary excretion of N-telopeptides actually reflects growth rate in children'? and is markedly increased in patients with postmenopausal osteoporosis (the values being inversely correlated with lumbar spine bone mineral density). I I The excretion values of this analyte adequately reflect suppression of bone turnover by oestrogen replacement therapy;12 moreover, in healthy subjects receiving diphosphonates the urinary excretion values of N-telopeptides are considered to reflect bone transplants the N-teloeptides showed the highest discriminating power (as compared with the excretion values of apparently healthy persons). In contrast, the pyridinium cross-links were the only markers able to detect significant changes in bone turnover after transplantation. The reasons for this discrepancy are not clear. ' After renal transplantation there was a relationship between all bone resorption markers examined and the serum concentrations of bone alkaline phosphatase which may be considered a marker of bone formation. This corresponds to our previous findings in patients receiving renal transplantation which showed a 'coupling' of bone formation and resorption." In contrast, no correlation could be found between 'intact' parathyroid hormone values and marker values of bone metabolism indicating that other factors (e.g., the immunosuppressive regimen) may influence the increase in bone turnover after renal transplantation.'
Interpreting the relationship between different resorption markers the following has to be taken into account: the urinary excretion of bone resorption markers show a marked intraindividual variability, II correlation coefficient values depend upon the concentration range examined and the correlation coefficients may reflect different facets of bone metabolism as well as different metabolic clearances of the analytes.
In conclusion, in patients with metabolic and malignant bone disease there are marked differences in the clinical usefulness of different biochemical markers of bone resorption both with respect to the underlying disease and whether the marker substance is used for diagnostic purposes or for follow-up examinations.
